For example, agents targeted at FMS-like tyrosine kinase 3 (FLT3) mutations, present in approximately 30% of patients and generally associated with poor outcomes [9], have been approved and are recommended for use in adults with R/R AML [8,10,11]. The gene discussed is FLT3; the disease is acute myeloid leukemia.